Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Clinical Biochemistry,Molecular Biology,General Medicine
Reference110 articles.
1. Singh P, Kumar V, Gupta SK, Kumari G, Verma M (2021) Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review. Med Oncol 38:1–16. https://doi.org/10.1007/s12032-021-01462-5
2. Westerweel PE, Te Boekhorst PA, Levin M-D, Cornelissen JJ (2019) New approaches and treatment combinations for the management of chronic myeloid leukemia. Front Oncol 9:665. https://doi.org/10.3389/fonc.2019.00665
3. Chereda B, Melo JV (2015) Natural course and biology of CML. Ann Hematol 94:107–121. https://doi.org/10.1007/s00277-015-2325-z
4. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S (1999) An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 94(5):1517–36
5. Huang X, Cortes J, Kantarjian H (2012) Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118:3123–3127. https://doi.org/10.1002/cncr.26679
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献